×

Do you want to link to this External Site and leave Amgen.co.uk?

YOU ARE NOW LEAVING THIS WEBSITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Do you want to link to this Amgen Site outside the UK and leave Amgen.co.uk?

YOU ARE NOW LEAVING THIS WEBSITE. Amgen Limited and Amgen Ireland Limited takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Please note, this page is intended for UK healthcare professionals. By clicking to enter this page you are confirming that you are a UK healthcare professional.

×

Do you want to link to this Amgen Site and leave Amgen.co.uk?

Please note this site is only intended for UK Healthcare professionals and UK patients that have been prescribed Prolia®

YOU ARE NOW LEAVING THIS WEBSITE.

Joint Working Initiatives


Title NORTHERN BONE HEALTH PROJECT – FALLS AND FRACTURE PREVENTION, A POPULATION APPROACH.

Organisations Involved

Northern Health Science Alliance (NHSA)

AMGEN Ltd

AHSN – North East and North Cumbria (NENC)

AHSN – Innovation Agency

AHSN- Yorkshire and Humber

AHSN- Health Innovation Manchester

Interface Clinical Services Limited (ICS)

Joint Working Project Description

The overall aim of the four Academic Health Science Networks (AHSNs) across the North of England, working in partnership with AMGEN, The Northern Health Science Alliance(NHSA) and Interface Clinical services (ICS) is to support the Northern Region in leading innovation by targeting fracture risk assessment and Bone Sparing Medication Review at a Primary Care level. The aim of the joint working project is to identify patients at high risk of fracture, evaluate medications, educate and treat patients with the sole aim of future fracture prevention. The project is due to complete March 2021.

Expected Outcomes

The joint working project is designed to support implementation of NICE CG 146.

Key outputs from the service may include the following:

  • Patient education around osteoporosis, including the importance of healthy diet and exercise
  • Optimisation of treatment and support for primary and secondary fracture prevention
  • Support for GP practices to achieve the QOF osteoporosis indicators
  • Establishment of a process and educational legacy for primary care NHS organisations that supports sustained quality improvement in the management of osteoporosis.
  • An evaluation of the project to determine the lessons learnt and the optimal way to scale the project nationally.

GB-PRO-0720-00011 July 2020



Title DENOSUMAB FOR OSTEOPOROSIS: PATIENT SELF ADMINISTRATION SERVICE.
Organisations Involved Amgen Ltd and Cardiff and Vale University Health Board
Joint Working Project Description
The aim of this one-year project is:
  • To implement a permanent Metabolic Bone Dept service model at Cardiff and Vale University Hospitals for patient self-administration of Denosumab (Prolia) [1] within a community setting. This follows from a successful pilot project implemented in June 2018 by Professor Mike Stone.
  • This joint working partnership supports Cardiff and Vale University Health Board with funding to recruit a dedicated Self Injection Band 7 Nurse for 1 year to provide training and support for Osteoporosis patients in self-administration of their 6monthly injection of Denosumab. Manage the prescribing process and onward patient journey and supporting the patient with their long-term condition.
  • Amgen will provide support for production of a Business Case which will be completed during the project to support the sustainability of the service into 2021 and beyond.
  • New and existing patients will be offered the choice of self-administering their Denosumab (Prolia) injections after a first initial clinical consultation and Denosumab injection at month 0 and a further self-administration training appointment at 6 months.
Expected Outcomes
  • Recruitment of a Band 7 Nurse in Cardiff and Value University Health Board Metabolic Bone Dept to provide capacity release from Metabolic Bone outpatients clinics.
  • Greater choice for patients in where their medicine is delivered. Patient education on Osteoporosis; including the importance of a healthy diet and exercise
  • Evaluation of the project can be made available for other NHS organisations that support management of Osteoporosis patients medicines closer to home.
  • Sustainability of the Self-Administration Service for the benefit of patients and NHS Wales
  • The project incorporates the principles of improved patient education, medicines optimisation and treatment close to home

The project conclusions will be published and shared with the wider NHS community.

1. https://www.medicines.org.uk/emc/product/568/smpc

GB-PRO-0520-00019 June 2020


 

Title IMPROVING THE IDENTIFICATION AND TREATMENT OF PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA (FH) AND THE SECONDARY PREVENTION OF PATIENTS WITH HIGH RISK CARDIOVASCULAR DISEASE IN PRIMARY CARE.

Organisations Involved Academic Health Science Network for the North East and North Cumbria (AHSN-NENC) and Amgen Ltd in collaboration with Clinical Commissioning Groups, GP Practices and CDRC (Clinical Digital Resource Collaborative)

Joint Working Project Description

The overall aims of this project are to:

  • Identify patients at high risk of Familial Hypercholesterolemia (FH), evaluate medications, educate and treat patients with the sole aim of reducing excess coronary heart disease risk and premature mortality associated with Familial Hypercholesterolemia (FH).
  • Increase the utilisation of the genetic screening programme across the AHSN footprint through better patient identification.
  • Identify patients at high risk of CVD (>10% 10 year CV risk) and ensure appropriate treatment and management.

  • Improve the patient experience by providing more specialist care within primary care and ensure better utilisation and more appropriate referrals to the specialist service base with the NHS Trust.
  • To continue to refine and develop the FH service model to be adopted both regionally and nationally.
Expected Outcomes

The expected outcomes from this project are as follows:

  • A written document to inform the treatment of Familial Hypercholesterolemia (FH) patients in primary care including information on implementing patient identification using a Familial Hypercholesterolemia (FH) patient identification tool and clinical review at a practice level.
  • A toolkit to include training materials on Familial Hypercholesterolemia (FH) and its treatment for healthcare professionals in primary care and the use of the Familial Hypercholesterolemia (FH) patient identification tool.
  • Implementation of NICE CG71 and the NHS long term plan.
The project incorporates the principles of improved patient education, medicines optimisation and treatment close to home.

GB-REP-0520-00016 May 2020



Title IMPLEMENTATION OF AN OPTIMISED LIPID MANAGEMENT PATHWAY ACROSS PRIMARY & SECONDARY CARE.
Organisations Involved Northumbria Healthcare NHS Foundation Trust & Amgen

This Project has been agreed as part of the Accelerated Access Collaborative (AAC) https://www.nice.org.uk/aac.

The AAC was formed in response to the independently-chaired Accelerated Access Review published in October 2016 The AAC brings industry, government and the NHS together to remove barriers to uptake of innovations, so that NHS patients have faster access to innovations that can transform care.

The AAC supports the rapid uptake of products from 7 high-potential technology areas, selected by leaders in the health and care system, with full evidence-based recommendations from NICE, and have potential to deliver cost-savings.

PCSK9 inhibitors for the management of hypercholesterolemia were selected as one of the seven NICE recommended rapid uptake products (RUP) to increase patient access and remove barriers across the health innovation landscape.

Funding announced by government in July 2017 is available through the new Accelerated Access Collaborative Pathway Transformation Fund (PTF) to help NHS organisations integrate the rapid uptake products into everyday practices. Delivered with the PTF seeks to improve equality of access to these products.

The PTF, in relation to PCSK9 inhibitors, combines funding from NHS England, Amgen and Sanofi for selected projects to meet the AAC objectives and increase PCSK9i uptake by addressing barriers such as:

  • Lack of patient identification
  • Inconsistent Pathways
  • Limited awareness
  • Restricted prescribing
  • Sporadic LDL-C measurement
  • Treatment complexity

19 applications relating to PCSK9 inhibitors from 12 AHSNs were submitted to the AAC for PFT funding (funding from NHS England, Amgen and Sanofi) and 6 were selected, including Northumbria Healthcare NHS Foundation Trust.

Joint Working Project Description

This project is a patient identification project, case finding across both Primary & Secondary care.

Currently there are specialist Lipid clinics operating on three different sites within the Trust, the project will deliver three aspects to improve and develop the current pathway.

  1. Identification of patients Post ACS.
  2. Retrospective identification of high-risk patients with Atherosclerotic Cardiovascular Disease (ASCVD) in the community.
  3. Pharmacist led lipid optimisation clinic. Patients identified prospectively in 1. or retrospectively for 2. and in whom Lipid management has not been optimised and may be eligible for medication which can currently only be prescribed in secondary care.
Expected Outcomes

The joint working project is designed to support implementation of NICE CG181, TA393 & TA394.

Key outputs from the project may include the following:-

  • As a result of lipid optimisation in patients, an Amgen product would be used in line with TA394
  • To demonstrate collaborative working with the NHS
  • To enhance Amgen’s reputation
  • Support the appropriate and timely prescription of lipid lowering therapy.
  • Implement appropriate escalation process for lipid lowering therapy
  • Implement new ways of working with deployment of multidisciplinary staff
  • Establishment of pharmacist led optimisation clinics
  • The project will allow support for GPs to achieve the PCN Direct Enhanced Services
  • Rapid access to a specialist lipid service
  • Optimisation of treatment and support in lipid management
  • To support implementation of NICE CG181/TA393/TA394

GB-REP-2000013 April 2020




Title

IDENTIFICATION AND MANAGEMENT OF FAMILIAL HYPERCHOLESTEROLEMIA (FH) & HIGH-RISK CVD PATIENTS IN IRISH GENERAL PRACTICE.

Organisations Involved

The Irish College of General Practitioners (ICGP) and Amgen Ireland Ltd.

Joint Working Project Description

This partnership aims to test the test the feasibility of a general practice-based model of care to increase the detection of FH and high-risk CVD patients in Irish general practice leading to earlier identification and management of their CV risk.

Expected Outcomes

Key Outputs from the Joint Working Agreement include:
  • An increase the number of cases of FH identified through the recording of LDL and family history and a greater proportion of patients receiving management for their LDL-C in a sample of general practices in Ireland.
  • The partnership will generate aggregate data on the prevalence of high-risk CVD including FH in the Irish setting and identify individuals who may benefit from additional management.
  • The data from this partnership will support policy inclusion for a clinical pathway for the diagnosis and management of these patients in General Practice the Irish Healthcare setting.

IE-NPS-2000001 April 2020


 


Title IMPROVING THE IDENTIFICATION AND MANAGEMENT OF PATIENTS WITH FAMILIAL HYPERCHOLESTEROLAEMIA AND PATIENTS WITH CARDIOVASCULAR DISEASE AND PRIMARY HYPERCHOLESTEROLAEMIA / MIXED DYSLIPIDAEMIA IN LEICESTERSHIRE AND RUTLAND.
Organisations Involved University Hospitals of Leicester NHS Trust and Amgen
Joint Working Project Description

This Project has been agreed as part of the Accelerated Access Collaborative (AAC). The AAC was formed in response to the independently-chaired Accelerated Access Review published in October 2016. The AAC brings industry, government and the NHS together to remove barriers to uptake of innovations, so that NHS patients have faster access to certain products that can transform care.

The AAC supports the rapid uptake of products from 7 high-potential technology areas, selected by leaders in the health and care system, with full evidence-based recommendations from NICE.

PCSK9 inhibitors for the management of hypercholesterolemia were selected as one of the seven NICE recommended rapid uptake products to increase patient access and remove barriers across the health innovation landscape.

Funding announced by government in July 2017 is available through the new Accelerated Access Collaborative Pathway Transformation Fund (PTF) to help NHS organisations integrate the rapid uptake products into everyday practice. Delivered with the support of the Academic Health Science Networks (AHSNs) the PTF seeks to improve equality of access to these products.

The PTF, in relation to PCSK9 inhibitors, combines funding from NHS England, Amgen and Sanofi for selected projects to meet the AAC objectives and increase PCSK9i uptake by addressing barriers such as:

  • Lack of patient identification
  • Inconsistent pathways
  • Limited awareness
  • Restricted prescribing
  • Sporadic LDL-C measurement
  • Treatment complexity

19 applications relating to PCSK9 inhibitors from 12 AHSNs were submitted to the AAC for funding from NHS England, Amgen and Sanofi and 6 were selected, including University Hospitals of Leicester NHS Trust.

NHS England have provided Pathway Transformation Funding to the Academic Health and Science Network North East North Cumbria (AHSN-NENC). AHSN-NENC will distribute this accordingly as agreed by the AAC to the 6 successful sites, one of which being the Partner for this project.

The overall aim of University Hospitals of Leicester NHS Trust working in partnership with primary care and Amgen / Sanofi is to improve the identification and management of patients with familial hypercholesterolaemia (FH) and patients with cardiovascular disease and primary hypercholesterolaemia / mixed dyslipidaemia. Improved cholesterol management will reduce the cardiovascular disease risk for these patients.

UHL will seek to employ a clinical pharmacist or nurse with admin support to work on the project and achieve the following objectives:

  • Undertake a systematic search of GP records to identify patients with potential FH and patients with cardiovascular disease and primary hypercholesterolaemia / mixed dyslipidaemia.
  • Clinical pharmacist / nurse led review of high-risk patients in primary care to optimise cholesterol management.
  • Identification of patients with elevated LDL-C despite maximal lipid lowering medications and referral of these patients to the lipid clinic to review treatment options to improve LDL-C.
Expected Outcomes

Predicted Benefits for Patients

  • Increased diagnosis rate of FH and improved management of primary hypercholesterolaemia and mixed dyslipidaemia.
  • These patients can be initiated and / or treated with appropriate doses of cholesterol lowering medicines according to local guidelines which will lower their risk of cardiovascular disease / event (stroke, myocardial infarction or peripheral vascular disease).
  • These patients can be educated on cholesterol, diet, exercise and the importance of a healthy lifestyle.
  • Patient empowerment and engagement in terms of their diagnosis and subsequent clinical management plan (NICE – patient participation is of importance regarding decision making in terms of drug therapy etc)

Predicted Benefits for NHS Organisations

  • Reduce variation in identification and treatment of FH and primary hypercholesterolaemia and mixed dyslipidaemia across Leicestershire.
  • Assist PCNs in identifying and managing patients with cardiovascular disease in line with the NHS Long Term Plan
  • Supports implementation of NICE CG71.
  • Reduction in cardiovascular disease burden amongst Leicestershire patients will reduce associated hospital activity.

Predicted Benefits for Amgen

  • The project aims to increase the FH, hypercholesterolaemia and mixed dyslipidaemia diagnosis rates. Patients diagnosed with these conditions will be treated with cholesterol lowering medicines in line with local / national guidelines and NICE TA 394.
  • Demonstrates collaborative working with the NHS to the benefit of patients and identifies scalable solutions.

The results of the project will be written up and published to enable the learnings from the project to be shared.

UKIE-NPC-145-0320-082464a March 2020



Title

REDUCING CVD EVENTS BY OPTIMISING CHOLESTEROL MANAGEMENT FOR HIGH RISK PATIENTS IN THE NORTH WEST COAST REGION.


Organisations Involved

Amgen Limited and Innovation Agency NWC


Joint Working Project Description

The aim of the Project has been designed to support the delivery of the NHS CVD aspect of the Long-Term Plan.

The focus will be to improve cholesterol management, in Patients who are at a high risk of a CVD event or a further CVD event, to within parameters set by NICE guidelines with a focus on three areas:

  1. Support the clinical priority to reduce the number of CVD events.
  2. Ensure where appropriate, interventions are conducted in primary care by MDT teams within a primary care network (“PCN”) footprint.
  3. Use of population health analysis to identify cohorts of patients who are most in need of an intervention.
Expected Outcomes

Patients with persistently high cholesterol levels who are identified as high Risk for a CVD event or a further CVD event will be reviewed and managed optimally, as per NICE guidance CG181 AND CG71.

Audit tools, treatment and referral pathways as well as Primary Care upskilling to build on current management of Cholesterol will be reviewed with an expected reduction in CVD events as a direct result of optimising cholesterol levels in the practices involved in the project.  

UKIE-NPC-145-1219-080406a December 2019




Title ESTABLISHMENT OF A NATIONAL FRACTURE LIAISON SERVICE IN IRELAND.
Organisations Involved Royal College of Surgeons of Ireland (RCSI), FLS Steering Committee Ireland & Amgen Ireland Ltd
Joint Working Project Description

This partnership with the RCSI aims to establish a Fracture Liaison Service (FLS) database in existing FLS centres.  The FLS Database will collect data that demonstrates to policy makers support for a national FLS in all 16 trauma centres will improve care standards for osteoporosis patients, lead to early identification and treatment initiation to prevent further debilitating fragility fractures.

Expected Outcomes

Key outputs from the Joint Working Agreement include:

  • Demonstrate clinical and cost effectiveness of FLS, by increased identification, investigation & initiation of treatment.
  • Deliver KPI driven quality care improvement
  • Enable prescription initiation & adherence data
  • Development of FLS patient pathway

UKIE-NPC-NPS-1219-080190 December 2019




Title UPSKILLING PRIMARY CARE STAFF IN DETECTION, PROTECTION AND PERFECTION PATHWAY FOR PEOPLE WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA, PRIMARY HYPERCHOLESTEROLAEMIA AND MIXED DYSLIPIDAEMIA.
Organisations Involved West Midlands Academic Health Science Network and Amgen Ltd in collaboration with Strategic Transformation Partnerships, Primary Care Networks and GP Practices.
Joint Working Project Description

The overall aim of the project is to upskill primary care staff in the detection, protection and perfection pathway for people with heterozygous familial hypercholesterolemia, primary hypercholesterolaemia and mixed dyslipidaemia which will reduce the cardiovascular disease risk for these patients.

  • To create and implement a West Midlands wide pathway for the detection and management of Familial Hypercholesterolaemia (FH), primary hypercholesterolaemia and mixed dyslipidaemia. This will align with the WMAHSN strategy of “detect, protect and perfect”. Identification of people at risk of FH, primary hypercholesterolaemia and mixed dyslipidaemia and optimising their pharmacological management as well as addressing lifestyle changes and behaviours to improve overall health and well-being, is key to reducing the morbidity and mortality associated with poorly managed hypercholesterolaemia.
  • To upskill primary care practitioners in the basics of FH, primary hypercholesterolaemia and mixed dyslipidaemia management around the detection, protection and perfection
  • To provide examples of good practice through a collaborative multidisciplinary approach which utilises all sectors of the primary care workforce and specialists within secondary care.
  • To create a local network of FH, primary hypercholesterolaemia and mixed dyslipidaemia champions in regional areas to provide peer networking and support/encouragement
  • To evaluate the impact and health economics of the upskilling in identifying patients with FH, primary hypercholesterolaemia and mixed dyslipidaemia optimising their management (pharmacological and non-pharmacological), and quantifying the benefits in terms of healthcare resource utilisation and impact on productivity e.g. through reduction in the number of FH, primary hypercholesterolaemia and mixed dyslipidaemia related heart attacks
  • Ensure patients have access to the right medications, at the right dose and at the right time with appropriate follow up and review
  • Our approach will be to:
    • Conduct systematic FH searches as NICE clearly outlines a strategy for case finding and diagnosis which can be implemented locally.
    • Increase uptake of NHS Health Checks to individuals between the ages of 40 and 74 – total cholesterol is measured as part of this check.  Then screen as per the guidance above and refer into WMFHS being aware that QRISK cannot be applied to patients with FH because it will underestimate the CV risk in this population
Expected Outcomes

The joint working project is designed to improve the identification and treatment of patients with familial hypercholesterolaemia, primary hypercholesterolaemia and mixed dyslipidaemia with the sole purpose of reducing their cardiovascular risk.

Key outputs from the joint working project will be:

  • To improve the skills and knowledge of primary care clinicians in detecting and treating familial hypercholesterolaemia, primary hypercholesterolaemia and mixed dyslipidaemia.
  • To increase the diagnosis of familial hypercholesterolaemia, primary hypercholesterolaemia and mixed dyslipidaemia.
  • To produce a formal written evaluation of the project.

UKIE-NPC-145-1219-080175a December 2019




Title IMPROVING THE IDENTIFICATION AND MANAGEMENT OF PATIENTS WITH FAMILIAL HYPERCHOLESTEROLAEMIA AND PATIENTS WITH HIGH CHOLESTEROL RISK IN PRIMARY CARE.
Organisations Involved Kent Surrey and Sussex AHSN Limited (KSS AHSN) and Amgen Limited.
Joint Working Project Description

The overall aim of the Kent Surrey and Sussex Academic Health Science Network, in collaboration with the local Clinical Commissioning Groups, Primary Care Networks, GP practices and Amgen is to implement targeted FH and high cholesterol risk assessment and medication review at a primary care level.

Expected Outcomes

The aim of the joint working project is to:

  • Bring together Clinical Lipid Specialists to develop local prescribing guidelines and a lipid referral pathway across primary and secondary care.
  • Develop and roll out a training and education initiative for primary care clinicians and pharmacists to assist them in use of the various IT audit tools available and to appropriately identify, refer and manage patients with high cholesterol and FH.
  • Provide Primary Care Networks (PCN) and GP Practices with the audit tools and resources to enable them to identify patients at high risk of FH and high cholesterol, evaluate medications, educate and treat patients with the sole aim of eliminating the excess coronary heart disease risk and premature mortality associated with FH.
  • Improve the patient experience by providing targeted specialist care within primary care and ensure better utilisation and more appropriate referrals to the specialist service, based at the local NHS trust across Kent Surrey and Sussex.
  • Through better identification of high-risk patients, increase the use of the genetic screening programme.
  • To further develop an FH service model which can be scaled up nationally.

UKIE-NPC-145-1119-079763a December 2019